Alex brings nearly two decades of experience as a drug hunter, medicinal chemist and project leader to Parabilis Medicines. His track record of delivering oncology drug discovery projects from inception to the clinic has notably included C4 Therapeutics’ EGFR PROTAC, CFT8919, and AstraZeneca’s MCL1 inhibitor, AZD5991. Recently, as Vice President of Chemistry at Photys Therapeutics, Alex helped to build the company and led teams across scientific disciplines. Alex has built upon his foundation of traditional small molecule medicinal chemistry, leveraging new chemical modalities to elicit new biological function and address challenging targets, even those considered “undruggable.” Alex holds a B.A. and M.Sc. in natural sciences from the University of Cambridge and obtained his Ph.D. in organic chemistry under the supervision of Professor Amir Hoveyda at Boston College.